Nuvelo Discontinues Factor VIIa Inhibitor To Focus On Alfimeprase
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of the realignment, Nuvelo will cut its work force by 30 percent and reduce annual expenses by $15 million.
You may also be interested in...
Nuvelo Restarts Alfimeprase Trial For Central Venous Catheter Occlusion
The company is enrolling patients in the SONOMA-3 trial after an earlier trial, SONOMA-2, failed.
Nuvelo Restarts Alfimeprase Trial For Central Venous Catheter Occlusion
The company is enrolling patients in the SONOMA-3 trial after an earlier trial, SONOMA-2, failed.
For Now, Nuvelo Will Go It Alone On Thrombolytic Alfimeprase
Development of the stalled anti-clotting agent resumes as partner Bayer pulls out of the collaboration.